Ashley Chan

1 week ago | asianamericans.einnews.com | Ashley Chan

Despite several major United States (US) health organizations lowering the recommended starting age for colorectal cancer (CRC) screening to 45 years since 2018, the incidence of CRC in patients younger than 50 years of age is still on the rise, according to Jessica Paulus, ScD, who noted that social determinants of health could be contributing to earlier onset of CRC.1,2 Results from a real-world, retrospective analysis, which were presented at the 2025 ASCO Annual Meeting, demonstrated an...

1 week ago | cancernetwork.com | Ashley Chan

Bexobrutideg (NX-5948), a novel BTK degrader, was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), according to updated data from the phase 1 NX-5948-301 trial (NCT05131022) shared at the 2025 European Hematology Association Congress. At the data cutoff date of March 12, 2025, bexobrutideg demonstrated preliminary clinical activity in a population of heavily pretreated patients with advanced CLL.

1 week ago | onclive.com | Ashley Chan

Imetelstat (Rytelo) demonstrated clinical benefit in patients with ring sideroblast (RS)–negative lower-risk myelodysplastic syndromes (MDS) who were relapsed/refractory to or ineligible for erythropoiesis-stimulating agents (ESAs), according to data from a post hoc analysis from pooled populations from the phase 2/3 IMerge trial (NCT02598661).1 The data, which were presented at the 2025 EHA Congress, revealed that among 78 patients with RS-negative disease treated with imetelstat, 33%, 21%,...

1 week ago | onclive.com | Ashley Chan

Health Canada has approved quizartinib (Vanflyta) plus standard cytarabine and anthracycline induction with standard cytarabine consolidation chemotherapy, followed by quizartinib monotherapy as maintenance, for the treatment of adult patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia (AML).1 A validated test is necessary to confirm the FLT3-ITD status.

1 week ago | onclive.com | Ashley Chan

The May 2025 FDA approval of retifanlimab-dlwr (Zynyz) plus carboplatin/paclitaxel for the first-line treatment of patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) has provided a significant treatment option for this patient population, whose cancer is no longer considered rare, as incidence rates have increased within the past 20 years, according to Cathy Eng, MD, FACP, FASCO.1 The regulatory decision was supported by data from the...